Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Chinese Tech Stocks CCP Paranoia and Best AI Tech Stocks ETF - 26th Oct 21
Food Prices & Farm Inputs Getting Hard to Stomach - 26th Oct 21
Has Zillow’s Collapse Signaled A Warning For The Capital Markets? - 26th Oct 21
Dave Antrobus Welcomes Caribou to Award-Winning Group Inc & Co - 26th Oct 21
Stock Market New Intermediate uptrend - 26th Oct 21
Investing in Crypto Currencies With Both Eyes WIDE OPEN! - 25th Oct 21
Is Bitcoin a Better Inflation Hedge Than Gold? - 25th Oct 21
S&P 500 Stirs the Gold Pot - 25th Oct 21
Stock Market Against Bond Market Odds - 25th Oct 21
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Bio-Tech Stock That Will Profit from a New Breakthrough Medical Direction

Companies / BioTech Dec 02, 2014 - 03:26 PM GMT

By: Money_Morning

Companies

Ernie Tremblay writes: Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.

But return a patient to normal, optimal health?


Seldom…

So when an innovation comes along that can effect a complete and permanent remission of disease or restore damaged organs to a pristine state, it should cause your keenest investing instincts to perk up and pay attention…

A $1.8 Billion Start That's Headed Straight Up

That innovation is here, in the form of a revolutionary approach to curing disease and healing injury, and it's taking the research establishment by storm.

Biotech and pharmaceutical companies around the world are using it to create whole new classes of drugs and diagnostic tools that actually promise to cure heretofore incurable diseases – and create unimaginable wealth in the process.

It's a total game changer. And we can profit from it.

The idea is simply this: with current technologies, it's possible to design drugs, such as cell therapy products, that can be altered or optimally combined to fit the genetic and morphological profile of each individual patient, often recruiting his or her own immune system into the fight.

It's the opposite of the traditional one-drug-fits-all approach, and it's called personalized or regenerative medicine.

Instead of the old model, it treats every sick individual as a unique instance of patient meets pathogen.

It holds the promise of miraculous treatments for severe spinal injuries, joint and bone repair, and organ replacement, and may provide real-life "magic bullets" for diseases like cancer, multiple sclerosis, lupus, and inflammatory bowel disease (Crohn's and ulcerative colitis).

This is not science fiction or fanciful speculation.

In fact, some of these new, experimental medications have already proven completely curative in early trials against some cancers. And according to the Alliance of Regenerative and Personalized Medicine (ARM), current cell therapy products alone generated over $900 million in revenue with 160,000 patients receiving treatments.

If you add in other types of regenerative medicine products, that number doubles.

There are currently more than 2,500 clinical trials underway that use personalized medicine. About 400 of them are taking place in the labs of biotech and pharmaceutical companies.

And that's just the start.

Personalized Medicine in Action

Personalized medicine generally falls into three categories:

  • Rejuvenation. This is not about taking years off of your appearance. Instead, it means enhancing the body's ability to heal itself by repairing and replacing damaged tissue. You see this process at work when you have a skin cut or a broken bone. But researchers are currently finding ways to exploit and boost the body's ability to do the same thing with heart, lung, and nerve tissue.
  • Replacement. This means replacing unhealthy tissue with healthy tissue – from a donor or the patient themselves. This includes organ transplants, which have been going on for a long time, but researchers are currently enhancing the science by investigating new ways to overcome organ rejection by the immune system.
  • Regeneration. In this type of personalized medicine, potent stem cells or bioengineered cell products are delivered to diseased tissues or organs, where they can rebuild tissue and restore function. Often, a patient's own cells are removed, re-engineered to do a specific job, and returned to the patient.

Certain illnesses have proven stubbornly resistant to medications designed to keep them under long-term control. That's because they're amazingly complex and actually differ in pathology – the way they function – from person to person.

For example, IBD (Crohn's disease and ulcerative colitis) depend not only upon a patient's particular genetic make-up, but also upon the local environment in the gut – what's called the microbiome, or the sum total of organisms that live in the intestines – and how these two factors interplay with each other.

To treat an individual, it may well be necessary to understand how the various bacterial, viral, and fungal populations in his or her lower digestive tract are distributed, how they interact with various types of cells in the intestinal lining, and how they affect vulnerable locations in the genome.

New medications may be crucial to altering those populations, cells, or genome loci in very particular, individualized ways.

And certainly, new diagnostic tools will be essential to determining which medications are needed, in what combination, and at which doses.

Immunotherapy is one of many approaches to personalized medicine that has recently shown particular promise.

At the University of Pennsylvania, researchers are collecting the blood of leukemia patients and reengineering the genomes of their T-cells – powerful attack dogs of the human immune system – to recognize and hunt down cancer cells.

They then re-introduce the supercharged blood back into the patient from which it was taken, sometimes with astonishingly effective results. This technique is called CART or CTL019, and the FDA has designated it as breakthrough therapy, which will help speed it through the pipeline and into clinical use.

The only question left for us is how to take advantage of the opportunity in this exciting new space…

"An extraordinary opportunity for the long-term investor"

One biotech stock I find particularly interesting is Organovo Holdings Inc. (NYSE: ONVO).

Organovo develops and markets functional human tissues for use in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

It makes the tissue with an exciting new technology called 3D Bioprinting, which identifies key architectural and compositional elements of a target tissue, and then creates a design that can be utilized by a "bioprinter" to generate that tissue in the laboratory.

Organovo has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L' Oreal. The company was founded in 2007 and is headquartered in San Diego, California.

ONVO is currently trading at $6.25 per share, with a market cap of about $497 million.

The possibilities for using this company's products in both medical research and in clinical applications represent limitless income potential – and, I believe, an extraordinary opportunity for the long-term investor.

Source : http://moneymorning.com/2014/12/02/one-stock-that-will-profit-from-a-new-breakthrough-medical-direction/

Money Morning/The Money Map Report

©2014 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in